Deep research
About ACE-031
ACE-031 (also designated ACVR2B-Fc or RAP-031) is a recombinant fusion protein consisting of the extracellular ligand-binding domain of the human activin type IIB receptor (ActRIIB, amino acids 19-134) fused to the Fc portion of human IgG1 via a minimal linker. The resulting homodimeric protein has a molecular weight of approximately 90 kDa and functions as a soluble decoy receptor that circulates in the bloodstream, binding and neutralizing multiple members of the TGF-beta superfamily before they can engage cellular receptors on muscle, bone, and fat tissue.
The mechanism of action exploits the natural ligand-receptor biology of the TGF-beta superfamily. Under normal physiology, myostatin (GDF-8), activin A, activin B, GDF-11, and other TGF-beta ligands bind to the type IIB activin receptor on muscle cell surfaces, triggering Smad2/3 phosphorylation and downstream transcriptional programs that limit muscle mass. Myostatin is the most potent of these negative regulators: myostatin knockout animals (Belgian Blue cattle, Mighty Mice) develop approximately twice normal muscle mass. ACE-031 intercepts these ligands in the extracellular space with high affinity, preventing them from reaching cellular receptors. Binding affinities measured by surface plasmon resonance: myostatin Kd ~0.8 nM, activin A Kd ~0.3 nM, GDF-11 Kd ~0.5 nM.
ACE-031 was developed by Acceleron Pharma (Cambridge, MA) specifically for Duchenne muscular dystrophy (DMD), a devastating X-linked genetic disease caused by dystrophin deficiency that leads to progressive muscle wasting and premature death. In a Phase 2 clinical trial, DMD patients receiving a single subcutaneous dose of ACE-031 showed increased lean body mass, decreased fat mass, and improved bone mineral density, with effects detectable within 2 weeks and persisting for 4-6 weeks after a single dose. The trial was paused when some patients developed minor vascular effects (epistaxis, telangiectasia), which were attributed to the broad ligand-trapping profile (particularly inhibition of BMP9/BMP10, which regulate vascular remodeling).
In a separate study in healthy postmenopausal women, a single subcutaneous dose of ACE-031 increased thigh muscle volume by 3.3% (measured by MRI) and decreased fat mass, demonstrating that the compound promotes muscle growth even in the absence of disease. These anabolic effects occurred without exercise or dietary intervention.
The successor molecule ACE-083, which was designed for local intramuscular injection to avoid systemic vascular effects, continued in clinical development for facioscapulohumeral dystrophy (FSHD). Luspatercept (ACE-536), a related ActRIIB-Fc trap with modified ligand selectivity, received FDA approval as Reblozyl for treatment of anemia in myelodysplastic syndromes and beta-thalassemia, validating the therapeutic concept of TGF-beta ligand trapping.
Pharmacokinetically, ACE-031 has a long circulating half-life of approximately 10-14 days due to the IgG1 Fc domain engaging the neonatal Fc receptor (FcRn), which recycles the protein from endosomes back into circulation. This long half-life allows infrequent dosing (every 2-4 weeks). Subcutaneous bioavailability is estimated at 50-70%. The protein distributes primarily in the vascular and interstitial compartments.
For storage, ACE-031 should be stored at 2-8C (refrigerated) as a liquid formulation or at -20C for long-term storage of lyophilized powder. Do not freeze the liquid formulation. Once reconstituted from lyophilized form, use within 24-48 hours. The protein is sensitive to shaking and surface denaturation; handle gently and do not vortex. Store upright and protect from light.
Safety observations from clinical trials noted that ACE-031 at doses of 0.5-3 mg/kg produced the desired muscle anabolic effects. Dose-limiting observations included minor bleeding events (epistaxis in 3-5% of subjects) and superficial telangiectasia, attributed to BMP9/10 inhibition affecting vascular endothelial homeostasis. These effects were reversible upon discontinuation. No immune responses (anti-drug antibodies) were detected. No hepatotoxicity, nephrotoxicity, cardiac toxicity, or endocrine disruption was observed.